SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.
复制标题
DOI：
10.1016/j.jaut.2022.102906
复制
发表时间：
2022-10
影响因子：
12.8
通讯作者：
Wahlin, Staffan
中科院分区：
文献类型：
--
作者：
Efe, Cumali;Tascilar, Koray;Gerussi, Alessio;Bolis, Francesca;Lammert, Craig;Ebik, Berat;Stattermayer, Albert Friedrich;Cengiz, Mustafa;Gokce, Dilara Turan;Cristoferi, Laura;Peralta, Mirta;Massoumi, Hatef;Montes, Pedro;Cerda, Eira;Rigamonti, Cristina;Yapali, Suna;Adali, Gupse;Caliskan, Ali Riza;Balaban, Yasemin;Eren, Fatih;Eskazan, Tugce;Barutcu, Sezgin;Lytvyak, Ellina;Zazueta, Godolfino Miranda;Kayhan, Meral Akdogan;Heurgue-Berlot, Alexandra;De Martin, Eleonora;Yavuz, Ahmet;Biyik, Murat;Narro, Graciela Castro;Duman, Serkan;Hernandez, Nelia;Gatselis, Nikolaos K.;Aguirre, Jonathan;Idilman, Ramazan;Silva, Marcelo;Mendizabal, Manuel;Atay, Kadri;Guzelbulut, Fatih;Dhanasekaran, Renumathy;Montano-Loza, Aldo J.;Dalekos, George N.;Ridruejo, Ezequiel;Invernizzi, Pietro;Wahlin, Staffan
缺乏有关接种疫苗的自身免疫性肝炎 (AIH) 患者 2019 年冠状病毒病 (COVID-19) 结果的数据。我们评估了接受至少一剂辉瑞 BioNTech (BNT162b2)、Moderna (mRNA-1273) 或阿斯利康 (ChAdOx1-S) 疫苗的 AIH 患者的 COVID-19 结局。我们对患有 COVID-19 的 AIH 患者进行了回顾性研究。将至少接种一剂 COVID-19 疫苗后发生急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 突破性感染的 AIH 患者的结局与未接种疫苗的 AIH 患者进行比较。根据疾病过程中的临床状态，将COVID-19的结果分为：（i）未住院，（ii）住院但不吸氧，（iii）住院并通过鼻导管或面罩吸氧，（iv）入住重症监护病房（ICU）接受无创机械通气，（v）入住ICU接受有创机械通气或（vi）死亡，并使用序数逻辑回归分析数据。我们纳入了 413 名（258 名未接种疫苗和 155 名已接种疫苗）患者（81%，女性），确诊时的中位年龄为 52 岁（范围：17-85）岁。未接种疫苗和接种疫苗的 COVID-19 AIH 患者的住院率（36.4% vs. 14.2%）、需要补充氧气的比率（29.5% vs. 9%）和死亡率（7% vs. 0.6%）。在调整年龄、性别、合并症和肝硬化后，接受至少一剂 SARS-CoV-2 疫苗与 COVID-19 严重程度恶化的风险显着降低相关（调整后的比值比 [aOR] 0.18，95% 置信区间 [CI]，0.10-0.31）。总体而言，针对 SARS-CoV-2 的疫苗接种与 COVID-19 死亡风险显着降低相关（aOR 0.20，95% CI 0.11-0.35）。 SARS-CoV-2 疫苗接种可显着降低 AIH 患者的 COVID-19 严重程度和死亡率风险。
Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.
登录
查看更多内容
DOI：
10.1016/j.cmi.2021.09.036
发表时间：
2022-03
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Galmiche S;Luong Nguyen LB;Tartour E;de Lamballerie X;Wittkop L;Loubet P;Launay O
通讯作者：
Launay O
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1111/cts.12908
发表时间：
2021-03
期刊：
Clinical and translational science
影响因子：
--
作者：
Pascolini S;Vannini A;Deleonardi G;Ciordinik M;Sensoli A;Carletti I;Veronesi L;Ricci C;Pronesti A;Mazzanti L;Grondona A;Silvestri T;Zanuso S;Mazzolini M;Lalanne C;Quarneti C;Fusconi M;Giostra F;Granito A;Muratori L;Lenzi M;Muratori P
通讯作者：
Muratori P
DOI：
10.3390/v14020207
发表时间：
2022-01-21
期刊：
Viruses
影响因子：
--
作者：
Bakasis AD;Bitzogli K;Mouziouras D;Pouliakis A;Roumpoutsou M;Goules AV;Androutsakos T
通讯作者：
Androutsakos T
影响因子：
3.8
作者：
Chauhan M;Nzeako I;Li F;Thuluvath PJ
通讯作者：
Thuluvath PJ